Tezepelumab-ekko (Tezspire®)

Tezspire (tezepelumab‑ekko) is covered as add‑on maintenance therapy for FDA‑approved severe asthma in patients aged ≥12 and is not supported for non‑FDA indications or use in patients <12. Initial approval (6 months) requires ≥3 months of prior inhaled corticosteroid plus another controller, objective evidence of uncontrolled asthma (e.g., ≥2 steroid‑treated exacerbations, ≥1 hospitalization/ER/urgent care visit, FEV1 <80% predicted, FEV1/FVC <0.80, or worsening with steroid taper), and prescription by/consultation with an allergist/immunologist/pulmonologist; reauthorization requires ≥6 months of Tezspire, continued ICS use, documented clinical improvement, dosing of 210 mg SC every 4 weeks, and renewals are for 12 months.

"FDA-Approved Indication: Tezspire is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma."